arrow
S

Sherilyn A. Tuazon

Fred Hutchinson Cancer Center
H指数:12
被引数:1,768

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Impact of Gamma-Secretase Inhibition on Outcomes Following BCMA CAR-T Therapy in Multiple Myeloma: A Comparison of Two Phase 1 Trials

Gamma-分泌酶抑制剂对BCMA CAR-T疗法后多发性骨髓瘤结局的影响:两项I期试验的比较

2025-09-080
PRE
Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Updated Follow-up of Transcend CLL 004

Lisocabtagene Maraleucel (liso-cel) 在复发或难治性 (R/R) 慢性淋巴细胞白血病 (CLL)/小淋巴细胞淋巴瘤 (SLL) 患者中的疗效:Transcend CLL 004 研究的随访更新。

BLOOD
IF23.1
2024-11-050
PRE
Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004) a multicentre, open-label, single-arm, phase 1-2 study
LANCET
IF88.5
2023-08-0149
PRE
Yttrium-90 Anti-CD45 Immunotherapy Followed by Autologous Hematopoietic Cell Transplantation for Relapsed or Refractory Lymphoma

钇-90 Anti-CD45免疫治疗后自体造血干细胞移植治疗复发或难治性淋巴瘤

2021-01-017
OAAI
Pre-transplantation novel agent induction predicts progression-free survival for patients with immunoglobulin light-chain amyloidosis undergoing high-dose melphalan and autologous stem cell transplantation

移植前新型药物诱导可预测接受大剂量美法仑和自体干细胞移植的免疫球蛋白轻链淀粉样变性患者的无进展生存期

2016-11-235
OAAI